8/102 sources · 2 publishersUpdated Oct 8, 15:30 UTC
Nektar Therapeutics reports mid‑stage alopecia trial results, shares drop
Nektar Therapeutics released data from its REZOLVE‑AA mid‑stage trial of rezpegaldesleukin for alopecia. The low dose achieved a six‑month benefit in 29% of patients and the high dose in 31%. Despite the positive signals, the stock fell toward an eight‑month low.
Why it matters
The share decline shows investors reacted negatively to the modest efficacy rates, potentially limiting near‑term market enthusiasm for the drug.
Key facts
- 1The low dose showed 29% of patients benefited for six months without treatment. investors.com
- 2The high dose showed 31% of patients benefited for six months without treatment. investors.com
- 3The trial drug is rezpegaldesleukin. investors.com
- 4Data came from the REZOLVE‑AA trial. seekingalpha.com
- 5Nektar shares fell after the data release. investors.com
- 6The stock neared an eight‑month low. seekingalpha.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.